Abbott Labs’ proposed $5.8bn acquisition of Alere will give its IVD sales a significant boost and propel the company up the ranks to become the sector’s No. 2, behind Roche.
Abbott announced Feb. 1 that it has definitively agreed to pay $56 per share to acquire Waltham, Massachusetts-based Alere. The offer price represents a 50% premium over Alere’s $37.20 closing price on Friday Jan